Umbilical cord blood-derived CD133 positive cells for treatment of myocardial infarction
This study aims to test the potential of umbilical cord blood-derived CD133 cells in treating myocardial infarction. Umbilical cord blood-derived CD133 cells were isolated using magnetic activated cell sorting (MACS) and were infused into a myocardial infarction rat model. Treatment prevented scar thinning, attenuated systolic dilatation, and improved left ventricle function.
Read More
Product Information for
Umbilical cord blood-derived CD133 positive cells for treatment of myocardial infarction